The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|1|57-70

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.1, 2015-04, pp. : 57-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular and Clinical Follow-Up after Treatment of Multiple Myeloma

By  

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 105-110

Karger

Access to resources Recommend Favorite

Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents

By Madan Sumit   Kumar Shaji  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 415-429

Future Medicine

Access to resources Recommend Favorite

Vitamin D and multiple sclerosis: what is the clinical impact?

By Berlanga-Taylor Antonio J  

Expert Opinion on Medical Diagnostics, Vol. 7, Iss. 3, 2013-05 ,pp. : 227-229

Informa Healthcare

Access to resources Recommend Favorite

The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene

By  

CLINICAL ENDOCRINOLOGY, Vol. 82, Iss. 4, 2015-04 ,pp. : 543-549

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multiple myeloma

By  

TRENDS IN UROLOGY AND MEN'S HEALTH, Vol. 6, Iss. 1, 2015-01 ,pp. : 31-34

John Wiley & Sons Inc

Access to resources Recommend Favorite